However, as ICI only shows efficiency in some metastatic melanoma patients (majority of cutaneous melanoma), this study examined the clinical relevance of CD8+ TIL and CD20+ tumour infiltrating B cells and the genomic mutational landscape in different subtypes of 23 metastatic melanoma patients treated with immune checkpoint inhibitors (ICI). This evidence concerns the gene CD8A and cutaneous melanoma.